Browse F11R

Summary
SymbolF11R
NameF11 receptor
Aliases PAM-1; JCAM; JAM-1; JAM-A; JAMA; CD321; JAM1; junctional adhesion molecule 1; JAM; platelet F11 receptor; pl ......
Chromosomal Location1q21.2-q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell junction, tight junction Cell membrane Single-pass type I membrane protein Note=Localized at tight junctions of both epithelial and endothelial cells.
Domain PF07686 Immunoglobulin V-set domain
Function

Seems to play a role in epithelial tight junction formation. Appears early in primordial forms of cell junctions and recruits PARD3 (PubMed:11489913). The association of the PARD6-PARD3 complex may prevent the interaction of PARD3 with JAM1, thereby preventing tight junction assembly (By similarity). Plays a role in regulating monocyte transmigration involved in integrity of epithelial barrier (By similarity). Ligand for integrin alpha-L/beta-2 involved in memory T-cell and neutrophil transmigration (PubMed:11812992). Involved in platelet activation (PubMed:10753840). ; FUNCTION: (Microbial infection) Acts as a receptor for Mammalian reovirus sigma-1. ; FUNCTION: (Microbial infection) Acts as a receptor for Human Rotavirus strain Wa.

> Gene Ontology
 
Biological Process GO:0001885 endothelial cell development
GO:0002064 epithelial cell development
GO:0003013 circulatory system process
GO:0003158 endothelium development
GO:0007009 plasma membrane organization
GO:0007043 cell-cell junction assembly
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0007179 transforming growth factor beta receptor signaling pathway
GO:0007586 digestion
GO:0008015 blood circulation
GO:0008217 regulation of blood pressure
GO:0009314 response to radiation
GO:0019058 viral life cycle
GO:0022600 digestive system process
GO:0030198 extracellular matrix organization
GO:0030260 entry into host cell
GO:0031032 actomyosin structure organization
GO:0031532 actin cytoskeleton reorganization
GO:0032956 regulation of actin cytoskeleton organization
GO:0032970 regulation of actin filament-based process
GO:0034260 negative regulation of GTPase activity
GO:0034329 cell junction assembly
GO:0034330 cell junction organization
GO:0043062 extracellular structure organization
GO:0043297 apical junction assembly
GO:0044409 entry into host
GO:0045216 cell-cell junction organization
GO:0045446 endothelial cell differentiation
GO:0045777 positive regulation of blood pressure
GO:0046718 viral entry into host cell
GO:0050892 intestinal absorption
GO:0050900 leukocyte migration
GO:0051346 negative regulation of hydrolase activity
GO:0051493 regulation of cytoskeleton organization
GO:0051701 interaction with host
GO:0051806 entry into cell of other organism involved in symbiotic interaction
GO:0051828 entry into other organism involved in symbiotic interaction
GO:0061028 establishment of endothelial barrier
GO:0070830 bicellular tight junction assembly
GO:0071559 response to transforming growth factor beta
GO:0071560 cellular response to transforming growth factor beta stimulus
GO:0072657 protein localization to membrane
GO:0072659 protein localization to plasma membrane
GO:0090002 establishment of protein localization to plasma membrane
GO:0090150 establishment of protein localization to membrane
GO:0090557 establishment of endothelial intestinal barrier
GO:0090559 regulation of membrane permeability
GO:1990778 protein localization to cell periphery
GO:2000249 regulation of actin cytoskeleton reorganization
Molecular Function GO:0001618 virus receptor activity
GO:0030165 PDZ domain binding
GO:0045296 cadherin binding
GO:0050839 cell adhesion molecule binding
GO:0098631 protein binding involved in cell adhesion
GO:0098632 protein binding involved in cell-cell adhesion
GO:0098641 cadherin binding involved in cell-cell adhesion
Cellular Component GO:0005913 cell-cell adherens junction
GO:0005923 bicellular tight junction
GO:0036056 filtration diaphragm
GO:0036057 slit diaphragm
GO:0043296 apical junction complex
GO:0070160 occluding junction
> KEGG and Reactome Pathway
 
KEGG hsa04514 Cell adhesion molecules (CAMs)
hsa04530 Tight junction
hsa04670 Leukocyte transendothelial migration
Reactome R-HSA-446728: Cell junction organization
R-HSA-202733: Cell surface interactions at the vascular wall
R-HSA-1500931: Cell-Cell communication
R-HSA-421270: Cell-cell junction organization
R-HSA-1474244: Extracellular matrix organization
R-HSA-109582: Hemostasis
R-HSA-216083: Integrin cell surface interactions
R-HSA-162582: Signal Transduction
R-HSA-170834: Signaling by TGF-beta Receptor Complex
R-HSA-2173791: TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
R-HSA-420029: Tight junction interactions
Summary
SymbolF11R
NameF11 receptor
Aliases PAM-1; JCAM; JAM-1; JAM-A; JAMA; CD321; JAM1; junctional adhesion molecule 1; JAM; platelet F11 receptor; pl ......
Chromosomal Location1q21.2-q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between F11R and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between F11R and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
20160037Malignant Pancreatic InsulinomaInhibit immunity (infiltration)Inactivation of junctional adhesion molecule-A enhances antitumoral immune response by promoting dendritic cell and T lymphocyte infiltration. In the absence of JAM-A, tumors showed a small but significant reduction in angiogenesis and a marked increase in the immune reaction with enhanced infiltration of DCs (CD11c+ and MHC-II+) and CD4+ and CD8+ lymphocytes. These findings support the idea that, in the Rip1Tag2 tumor model, abrogation of JAM-A reduces cancer development by increasing antitumor immune response.
Summary
SymbolF11R
NameF11 receptor
Aliases PAM-1; JCAM; JAM-1; JAM-A; JAMA; CD321; JAM1; junctional adhesion molecule 1; JAM; platelet F11 receptor; pl ......
Chromosomal Location1q21.2-q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of F11R in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen Total # shRNA with >= 4-fold: 2 Resistant to T-cell proliferation
24476824shRNAmelanomaB16Secondary screen Total # shRNA with >= 4-fold: 3 Resistant to T-cell proliferation
Summary
SymbolF11R
NameF11 receptor
Aliases PAM-1; JCAM; JAM-1; JAM-A; JAMA; CD321; JAM1; junctional adhesion molecule 1; JAM; platelet F11 receptor; pl ......
Chromosomal Location1q21.2-q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of F11R in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14121.0830.0235
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.6610.368
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.6650.616
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.480.285
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.4050.853
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5760.837
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2710.572
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.6880.664
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2590.889
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2450.884
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.4910.846
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.3290.00932
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of F11R in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.74.1-0.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.75.1-1.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.55.93.61
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.516.7-4.21
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolF11R
NameF11 receptor
Aliases PAM-1; JCAM; JAM-1; JAM-A; JAMA; CD321; JAM1; junctional adhesion molecule 1; JAM; platelet F11 receptor; pl ......
Chromosomal Location1q21.2-q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of F11R. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolF11R
NameF11 receptor
Aliases PAM-1; JCAM; JAM-1; JAM-A; JAMA; CD321; JAM1; junctional adhesion molecule 1; JAM; platelet F11 receptor; pl ......
Chromosomal Location1q21.2-q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of F11R. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by F11R.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolF11R
NameF11 receptor
Aliases PAM-1; JCAM; JAM-1; JAM-A; JAMA; CD321; JAM1; junctional adhesion molecule 1; JAM; platelet F11 receptor; pl ......
Chromosomal Location1q21.2-q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of F11R. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolF11R
NameF11 receptor
Aliases PAM-1; JCAM; JAM-1; JAM-A; JAMA; CD321; JAM1; junctional adhesion molecule 1; JAM; platelet F11 receptor; pl ......
Chromosomal Location1q21.2-q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of F11R expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolF11R
NameF11 receptor
Aliases PAM-1; JCAM; JAM-1; JAM-A; JAMA; CD321; JAM1; junctional adhesion molecule 1; JAM; platelet F11 receptor; pl ......
Chromosomal Location1q21.2-q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between F11R and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolF11R
NameF11 receptor
Aliases PAM-1; JCAM; JAM-1; JAM-A; JAMA; CD321; JAM1; junctional adhesion molecule 1; JAM; platelet F11 receptor; pl ......
Chromosomal Location1q21.2-q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting F11R collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.